Literature DB >> 15356555

Heat denaturation affects the ProDer p 1 IgE reactivity and downregulates the development of the specific allergic response.

Mauro Magi1, Lida Garcia, Michel Vandenbranden, Rémi Palmantier, Alain Jacquet.   

Abstract

BACKGROUND: Modified allergens with reduced IgE-binding activity represent an elegant approach to circumvent the risk of anaphylactic reactions in allergen-specific immunotherapy.
OBJECTIVE: The current work investigated the effect of heat denaturation on the allergenic properties of recombinant ProDer p 1, a precursor form of the major house dust mite allergen Der p 1.
METHODS: The IgE reactivity was estimated by direct and competition ELISA. The immunogenicity of heat-denatured ProDer p 1 was evaluated in naive and Der p 1-allergic mice.
RESULTS: Heat denaturation in reducing conditions drastically reduced the in vitro ProDer p 1 IgE reactivity toward human allergic sera. In naive mice, heat-denatured ProDer p 1 generated mixed T(H)1-T(H)2 responses characterized by the absence of specific IgE with concomitant rise in specific IgG2a titers and the presence of IL-5 and IFN-gamma in splenocyte cultures. In contrast, natural Der p 1 or native ProDer p 1 induced typical strict T(H)2-biased allergic responses with strong IgG1 and IgE titers, whereas spleen cells exhibited only high IL-5 secretion. Moreover, native or heat-denatured ProDer p 1 vaccinations prevented airway eosinophil infiltrations after challenge. Although native or heat-treated ProDer p 1 adjuvanted with SBAS1b induced mixed T(H)1-T(H)2 responses in allergic mice, heat-denatured ProDer p 1, compared with native ProDer p 1, proved to be more effective in redirecting the T(H)2-allergic response toward T(H)1.
CONCLUSION: Taken together, our results suggest that variants of Der p 1 with reduced IgE-binding reactivity could represent hypoallergenic molecules suitable for allergen-specific immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356555     DOI: 10.1016/j.jaci.2004.04.014

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  6 in total

1.  Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice.

Authors:  Vivek S Purohit; C Russell Middaugh; Sathyamangalam V Balasubramanian
Journal:  J Pharm Sci       Date:  2006-02       Impact factor: 3.534

Review 2.  Mite immunotherapy.

Authors:  Enrique Fernández-Caldas; Victor Iraola; Manuel Boquete; Antonio Nieto; Miguel Casanovas
Journal:  Curr Allergy Asthma Rep       Date:  2006-09       Impact factor: 4.806

3.  One mechanism of glucocorticoid action in asthma may involve the inhibition of IL-25 expression.

Authors:  Wei Lu; Chao Lu; Chengming Zhang; Chenghao Zhang
Journal:  Exp Ther Med       Date:  2016-12-27       Impact factor: 2.447

Review 4.  Antigen-specific tolerance in immunotherapy of Th2-associated allergic diseases.

Authors:  Charles B Smarr; Paul J Bryce; Stephen D Miller
Journal:  Crit Rev Immunol       Date:  2013       Impact factor: 2.214

5.  Gamma-irradiation of Streptococcus pneumoniae for the use as an immunogenic whole cell vaccine.

Authors:  Min Yong Jwa; Soyoung Jeong; Eun Byeol Ko; A Reum Kim; Hyun Young Kim; Sun Kyung Kim; Ho Seong Seo; Cheol-Heui Yun; Seung Hyun Han
Journal:  J Microbiol       Date:  2018-07-25       Impact factor: 3.422

6.  Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses.

Authors:  Marisa K Joubert; Martha Hokom; Catherine Eakin; Lei Zhou; Meghana Deshpande; Matthew P Baker; Theresa J Goletz; Bruce A Kerwin; Naren Chirmule; Linda O Narhi; Vibha Jawa
Journal:  J Biol Chem       Date:  2012-05-14       Impact factor: 5.157

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.